Interpace Biosciences is a diagnostics & research business based in the US. Interpace Biosciences shares (IDXG) are listed on the OTCQX (a marketplace for buying and selling "over the counter" stocks which aren't listed on a formal stock exchange) and all prices are listed in US Dollars. Its last market close was $2.68 – a decrease of 13.27% over the previous week. Interpace Biosciences employs 108 staff and has a trailing 12-month revenue of around $44.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.68 |
|---|---|
| 52-week range | $0.78 - $3.54 |
| 50-day moving average | $2.20 |
| 200-day moving average | $1.81 |
| Wall St. target price | $11.00 |
| PE ratio | 2.8091 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.675 from 2024-11-19
| 1 week (2024-11-14) | -13.43% |
|---|---|
| 1 month (2024-10-21) | -0.96% |
| 3 months (2024-08-21) | 80.74% |
| 6 months (2024-05-21) | 76.03% |
| 1 year (2023-11-21) | 154.76% |
|---|---|
| 2 years (2022-11-21) | 114.00% |
| 3 years (2021-11-19) | 7.75 |
| 5 years (2019-11-21) | 6.199 |
Valuing Interpace Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Interpace Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Interpace Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Interpace Biosciences shares trade at around 3x recent earnings.
Interpace Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 million.
The EBITDA is a measure of a Interpace Biosciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $44.9 million |
|---|---|
| Operating margin TTM | 15.49% |
| Gross profit TTM | $18.2 million |
| Return on assets TTM | 28.09% |
| Return on equity TTM | -284.81% |
| Profit margin | 10.47% |
| Book value | $-13.13 |
| Market Capitalization | $13.6 million |
TTM: trailing 12 months
We're not expecting Interpace Biosciences to pay a dividend over the next 12 months.
Interpace Biosciences's shares were split on a 1:10 basis on 14 January 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Interpace Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Interpace Biosciences shares which in turn could have impacted Interpace Biosciences's share price.
Over the last 12 months, Interpace Biosciences's shares have ranged in value from as little as $0.78 up to $3.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQX average) beta is 1, while Interpace Biosciences's is 0.625. This would suggest that Interpace Biosciences's shares are less volatile than average (for this exchange).
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.